Longhorn Vaccines and Diagnostics to Present Data on LHNVD-105, a Universal Vaccine Candidate, at ECCMID 2024
11 Apr 2024
VaccineClinical Study
Study examines how monoclonal antibodies mitigate influenza and mycobacterium tuberculosis
BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)-- Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024. ECCMID will take place online and in-person in Barcelona, Spain, from April 27-30, 2024.
The first two abstracts will detail data on LHNVD-105, an adjuvanted composite peptide universal influenza vaccine, and the monoclonal antibodies it produces. A third abstract will be presented by the University of Pretoria on Longhorn’s monoclonal antibodies for the prevention and treatment of infections caused by mycobacterium tuberculosis and gram-positive bacteria.
Abstract and presentation details are as follows:
Abstract Title: Adjuvanted unconjugated highly conserved multi-epitope influenza peptide vaccine induced broadly reactive antibodies to multiple influenza viruses in pigs
Poster Number: P0252
Session Title: 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)
Session Date/Time: April 27, 2024, 12:00
Session Location: Poster Area
Abstract Title: Neutralising monoclonal antibodies raised against highly conserved influenza hemagglutinin, neuraminidase, and matrix epitopes may offer novel cocktail therapeutic strategies
Poster Number: P0162
Session Title: 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance)
Session Date/Time: April 27, 2024, 12:00
Session Location: Poster Area
Abstract Title: Opsonic IgG2a and IgG2b monoclonal antibodies targeting gram-positive cell wall components heat shock protein and peptidoglycan recognise and bind to clinical Mycobacterium tuberculosis isolates
Poster Number: P3858
Session Title: 10f. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)
Session Date/Time: April 27, 2024, 12:00
Session Location: Poster Area
For more information about Longhorn, visit .
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines and Diagnostics is a closely held One Health company based in Maryland that is developing broad coverage vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing broad coverage vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn products play a significant role to surveil, diagnose, prevent and treat the next infectious disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.